(Diphtheria + pertussis (acellular) + tetanus) vaccine is under clinical development by BioNet-Asia and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect (Diphtheria + pertussis (acellular) + tetanus) vaccine’s likelihood of approval (LoA) and phase transition for Pertussis (Whooping Cough) took place on 28 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Diphtheria + pertussis (acellular) + tetanus) vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
(Diphtheria + pertussis (acellular) + tetanus) vaccine overview
TdaP vaccine is under development for the prevention of pertusis, tetanus and diphtheria. The vaccine candidate is administered intramuscularly. It constitutes of recombinant acellular pertussis vaccine containing recombinant genetically detoxified pertussis toxin (PTgen), filamentous hemagglutinin (FHA) and pertactin (PRN) in combination with tetanus and diphtheria toxoids.
BioNet-Asia (BioNet) is a unique vaccine expertise offering through its networks access to technology, products and markets. BioNet is headquartered in Bangkok, Thailand.
Quick View (Diphtheria + pertussis (acellular) + tetanus) vaccine LOA Data
|Highest Development Stage|